← 返回

识别 m6A 和铁死亡相关 lncRNA 特征用于预测肝细胞癌免疫疗效

英文原题:Identification of m6A- and ferroptosis-related lncRNA signature for predicting immune efficacy in hepatocellular carcinoma.

查看英文原题

Identification of m6A- and ferroptosis-related lncRNA signature for predicting immune efficacy in hepatocellular carcinoma.

PubMed 2022/08/11(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

mfrlncRNA 特征具有重要的预后价值,为识别“冷”和“热”肿瘤提供了新线索,并可能对个体化治疗以提高 HCC 患者生存率具有关键意义。

研究思路结论见上方概要

N6-甲基腺苷(m6A)甲基化和铁死亡协助长链非编码RNA(lncRNA)促进肝细胞癌(HCC)的免疫逃逸。然而,m6A和铁死亡相关lncRNA(mfrlncRNA)在免疫疗效方面的预测价值仍不清楚。

从癌症基因组图谱(TCGA)数据库中选取了365例数据完整的HCC患者作为训练队列,并随机抽取其中一半作为验证队列。从国际癌症基因组联盟(ICGC)数据库中选取了161例HCC患者作为外部验证(ICGC队列)。

我们首先鉴定了一组与 m6A 调控因子和铁死亡相关基因均相关的特异性 lncRNA,然后构建了预后相关的 mfrlncRNA 配对。在此基础上,利用最小绝对收缩和选择算子(LASSO)分析及 Cox 回归构建了 mfrlncRNA 特征。值得注意的是,患者的风险评分被证明是一个独立的预后因素,且优于 TNM 分期和肿瘤分级。此外,高风险评分患者的生存率较低,免疫抑制细胞(巨噬细胞和 Tregs)浸润较高,细胞毒性免疫细胞(NK 细胞)浸润较低,免疫疗效较差(免疫表型评分和肿瘤免疫功能障碍与排斥评分均较差),IC 50 较高,且诱导性 Treg 通路富集,这证实了 mfrlncRNA 特征有助于 HCC 患者的生存预测和风险分层。

展开英文摘要原文

N6-methyladenosine (m6A) methylation and ferroptosis assist long noncoding RNAs (lncRNAs) in promoting immune escape in hepatocellular carcinoma (HCC). However, the predictive value of m6A- and ferroptosis-related lncRNAs (mfrlncRNAs) in terms of immune efficacy remains unknown. METHOD: A total of 365 HCC patients with complete data from The Cancer Genome Atlas (TCGA) database were used as the training cohort, and half of them were randomly selected as the validation cohort. A total of 161 HCC patients from the International Cancer Genome Consortium (ICGC) database were used as external validation (ICGC cohort).

We first identified a group of specific lncRNAs associated with both m6A regulators and ferroptosis-related genes and then constructed prognosis-related mfrlncRNA pairs. Based on this, the mfrlncRNA signature was constructed using the least absolute shrinkage and selection operator (LASSO) analysis and Cox regression. Notably, the risk score of patients was proven to be an independent prognostic factor and was better than the TNM stage and tumor grade. Moreover, patients with high-risk scores had lower survival rates, higher infiltration of immunosuppressive cells (macrophages and Tregs), lower infiltration of cytotoxic immune cells (natural killer cells), poorer immune efficacy (both immunophenoscore and score of tumor immune dysfunction and exclusion), higher IC 50 , and enrichment of the induced Treg pathway, which confirmed that the mfrlncRNA signature contributed to survival prediction and risk stratification of patients with HCC.

The mfrlncRNA signature, which has great prognostic value, provides new clues for identifying "cold" and "hot" tumors and might have crucial implications for individualized therapy to improve the survival rate of patients with HCC.

论文信息

作者
Xie H、Shi M、Liu Y、Cheng C、Song L、Ding Z、Jin H、Cui X
单位
Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, and Medical School of Nantong University, Nantong, China.China
文献类型
非美国政府资助研究
期刊
Frontiers in immunology2022
原文标识
PubMed 36032107 · DOI 10.3389/fimmu.2022.914977